Sidley Austin represented Ocuphire Pharma, Inc. in the transaction, and Smith, Anderson, Blount, Dorsett, Mitchell & Jernigan represented Opus Genetics Inc. Wilson Sonsini Goodrich & Rosati...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini Goodrich & Rosati advised General Atlantic on patent matters related to the transaction. Seaport Therapeutics (Seaport), a clinical-stage biopharmaceutical company that is advancing novel...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini Goodrich & Rosati advised Goldman Sachs Alternatives on patent matters related to the transaction. Triveni Bio, a biotech company, announced the completion of a...
You must be a Standard 1 Year member to access this content.
Morrison & Foerster advised Crinetics Pharmaceuticals, Inc. on the offering, Wilson Sonsini Goodrich & Rosati advised Crinetics on patent matters and Cooley advised the underwriters. Crinetics...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini Goodrich & Rosati advised 858 Therapeutics on intellectual property matters related to the transaction. 858 Therapeutics announced raising $50 million in a Series B...
You must be a Standard 1 Year member to access this content.
Goodwin Procter and Wilson Sonsini Goodrich & Rosati represented MBX Biosciences, Inc. in the offering, and Davis Polk & Wardwell represented the underwriters. MBX Biosciences, Inc....
You must be a Standard 1 Year member to access this content.
Latham & Watkins advised Avidity Biosciences on the deal, and Wilson Sonsini Goodrich & Rosati acted as patent counsel to Avidity. Avidity Biosciences, Inc. (Nasdaq: RNA),...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini Goodrich & Rosati advised MBX Biosciences on patent matters on the transaction. MBX Biosciences, Inc., a clinical-stage biopharmaceutical company, announced a $63.5 million Series...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini Goodrich & Rosati advised Autobahn Therapeutics on the transaction. Autobahn Therapeutics, a biotechnology company, announced the closing of an oversubscribed $100 million Series C...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini Goodrich & Rosati advised Dren Bio on the transaction. Dren Bio, Inc., a privately held, clinical-stage biopharmaceutical company developing antibody therapeutics for cancer, autoimmune,...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini Goodrich & Rosati advised Vida Ventures on IP matters related to the transaction. Third Arc Bio Inc., a biotech company, announced a $165 million...
You must be a Standard 1 Year member to access this content.
Cooley advised Radionetics Oncology on the transaction, and Wilson Sonsini Goodrich & Rosati acted as patent counsel for Radionetics Oncology and advised the company on patent....
You must be a Standard 1 Year member to access this content.
